Navigation Links
PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Date:4/14/2009

- Study Meets Primary Endpoint Showing Statistically Significant Improvement in Overall Survival -

- First Active Immunotherapy for Cancer to Prolong Survival -

- Full Data to be Presented at Plenary Session at Upcoming AUA Annual Meeting -

- Company to Host a Conference Call Today at 9:00 AM ET -

SEATTLE, April 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control. The magnitude of the survival difference observed in the intent to treat population resulted in the study successfully achieving the pre-specified level of statistical significance defined by the study's design. The safety profile of PROVENGE appeared to be consistent with prior trials.

The 512-patient, multi-center, randomized, double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study enrolled men with metastatic androgen-independent prostate cancer was conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA).

PROVENGE is Dendreon's investigational product candidate for men with advanced prostate cancer and may represent the first in a new class of active cellular immunotherapies specifically designed to engage the patient's own immune system against cancer.

Detailed results from the IMPACT study will be presented during a plenary session at the American Urological Association's Annual Meeting in Chicago on Tues., Apr. 28 at 2:20 pm CT.

"Survival is the gold standard outcome for oncology clinical trials, and overall survival
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
3. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
4. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
5. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
6. Study Shows Machine Perfusion Significantly Improves Transplant Results
7. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
8. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
9. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Sunnyvale, CA (PRWEB) November 25, 2014 ... joins forces with RPM Alliance , provider ... and pharmaceutical companies. With the latest addition to its ... only free validated EDC system to India. , ... as a robust and customizable EDC platform which is ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 Global ... by 2019 growing at an estimated CAGR of ... for healthy food products with least ecological impacts, ... mineral fertilizers to boost crop yield more effectively ... products that can improve the return on investments. ...
(Date:11/26/2014)... WILMINGTON, DE (PRWEB) November 26, 2014 ... MPN Heroes recognition reception on December 5, 2014, in ... annual meeting. The MPN Heroes event will honor clinicians, ... the field of myeloproliferative neoplasms (MPNs). , Special ... will discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... Bio-Techne Corporation (NASDAQ: TECH ) ... to serve in a newly created position of ... Gavin will be responsible for managing the operations of ... business acquired in July 2014 and the recently acquired ... -based ProteinSimple develops and commercializes proprietary systems and ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... coming out of California, but the failure of flight communications ... of the weirdest. , ,The radio system used by controllers ... snit when its regular monthly maintenance wasnt performed and shut ... couldnt talk to them, even as the planes converged well ...
... raised the premise that in the early years of biotech it ... health care. , ,Theres a thread drawn to the early ... making money but about expressing what was going on in society ... money and both have become industries that have become mainstream. , ...
... likely be a popular spot for wireless use. Source: Fitchburg ... green mixed-use development, is now home to a free wireless ... Systems put up, provides wireless access to about 16 ... prairie with trails and a large pavilion. , ,Besides Berbee, ...
Cached Biology Technology:Proactive nightmares 2Biotech IPOs bring in encouraging sums 2Biotech IPOs bring in encouraging sums 3Fitchburg tech campus offers free wireless access 2
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... Nov. 3, 2014 Research and Markets ... Therapy - Technologies, Markets and Companies" to their offering. ... technologies and methods, which have already started to play an ... transplantation is replacing the old fashioned bone marrow transplants. Role ... is bound to become a part of medical practice. ...
(Date:11/3/2014)... Researchers from Australia report that low birth weight and ... (OA)-related hip replacements in adulthood. Findings published in the ... & Research , indicate that low birth weight and ... arthroplasty due to OA as adults. , According ... of 25 are diagnosed with clinical OA. Symptoms of ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
... its host, the respiratory pathogen Pseudomonas aeruginosa takes ... adds three small molecules to turn it into a key ... be published May 7 in mBio , the online ... Emory University School of Medicine, the University of Virginia, and ...
... , On May 3, 2013, the NOAA GOES infrared and visible ... of smoke from the fire. The smoke plume is seen blowing ... 17 seconds and shows the smoke plume from May 3 at ... created by the NASA GOES Project, located at NASA,s Goddard Space ...
... MARC (Maximizing Access to Research Careers) Program has announced ... of Sports Medicine (ACSM) 60th Annual Meeting & 4th ... from May 28 June 1, 2013. These awards ... and scientists from underrepresented groups into the mainstream of ...
Cached Biology News:Pathogen turns protein into a virulence factor in 1 easy step 2Pathogen turns protein into a virulence factor in 1 easy step 3MARC travel awards announced for the 2013 60th Annual ACSM Meeting & 4th World Congress 2
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
... Clone/PAD: ZMD.368. Immunogen: Synthetic ... of the human WNT2B/WNT13 protein. ... human mouse and rat WNT2B/WNT13 proteins. ... isoforms. Reactivity: Mouse Human Rat ...
Request Info...
... Peptide sequences: Two separate ... corresponding to the same sequence used ... antiserum (Catalog No. 160890) ... with Cayman's guanylate cyclase polyclonal antiserum ...
Biology Products: